Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO: Zerlasiran in Elevated Lipoprotein(a)
NCT04606602Phase 1Completed
- Sponsor
- Silence Therapeutics
- Start
- Nov 2020
- Primary completion
- Aug 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of zerlasiran in elevated lipoprotein(a) (Lp(a)) (11 arms), sponsored by Silence Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events at Day 201. Started Nov 2020; status: completed.
02
Drugs
zerlasiran
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT04606602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606602.